Explore 3 Stock Ideas & Industry Insights Download Free Report

Nexalin Technology Inc

Company price
None USD 0.00(0%)
Last update at 2025-10-23T20:03:24.880338Z
Market Cap
0.00M

Momentum Score

…

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.11M
Revenue Per Share
0.01
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-107.05%
Net Debt
-0.58M
ROCE
-177.64%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -4.65M -1.70M -6.08M -3.40M -5.02M
Net income -4.65M -1.93M -6.16M -3.48M -5.02M
Selling general administrative 5.78M 2.79M 6.14M 3.47M 0.08M
Selling and marketing expenses 3.24M 0.89M 0.04M 0.01M 1.38M
Gross profit -1.30M 0.96M 0.12M 0.21M -0.01M
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M -
Ebit -5.70M -1.83M -6.02M -3.26M -1.47M
Ebitda -5.69M -1.66M -6.02M -3.26M -1.47M
Depreciation and amortization 0.00M 0.17M 0.00M 0.00M 0.00M
Operating income -5.70M -1.83M -6.02M -3.26M -1.47M
Other operating expenses 5.81M 3.15M 6.16M 3.50M 1.67M
Interest expense 0.04M 0.06M 0.08M 0.08M 0.08M
Net interest income -0.03M -0.06M -0.08M -0.08M -
Income tax expense -0.00M 0.23M 0.08M 0.08M 0.00M
Total revenue 0.11M 1.32M 0.14M 0.24M 0.21M
Total operating expenses 4.39M 2.79M 6.14M 3.47M 1.46M
Cost of revenue 1.41M 0.36M 0.02M 0.03M 0.22M
Total other income expense net 1.05M 0.14M -0.06M -0.15M -3.56M
Net income from continuing ops -4.60M -1.70M -6.08M -3.40M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3.63M 7.43M 0.75M 0.12M 0.11M
Intangible assets 0.11M - - - -
Other current assets 0.32M 0.27M 0.04M 0.01M 0.02M
Total liab 0.43M 1.95M 2.44M 1.71M 1.29M
Total stockholder equity 3.21M 5.48M -1.68M -1.59M -1.18M
Other current liab 0.26M 0.54M 0.61M 0.52M 0.13M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M -
Retained earnings -77.04M -72.39M -70.69M -64.61M -61.21M
Other assets 0.00M - - - -
Cash 0.58M 0.16M 0.66M 0.08M 0.06M
Total current liabilities 0.43M 1.95M 2.36M 1.57M 1.04M
Current deferred revenue - - 0.13M - -
Net debt -0.58M 0.59M 0.19M 0.65M 0.77M
Short term debt 0.00M 0.75M 0.78M 0.58M 0.59M
Short long term debt - 0.70M 0.74M 0.55M -
Short long term debt total 0.00M 0.76M 0.85M 0.73M 0.84M
Other stockholder equity 80.24M 77.82M 69.00M 63.02M 60.03M
Total current assets 3.43M 7.43M 0.75M 0.12M 0.11M
Long term investments 0.10M - - - -
Short term investments 2.37M 6.83M - - -
Net receivables 0.01M 0.00M 0.02M 0.01M 0.01M
Long term debt - - 0.02M 0.05M -
Inventory 0.16M 0.15M 0.03M 0.02M 0.02M
Accounts payable 0.16M 0.66M 0.84M 0.46M 0.32M
Accumulated other comprehensive income -0.00M 0.04M - - -
Non currrent assets other 0.10M - - - -0.00M
Non current assets total 0.20M 0.01M 0.00M 0.00M 0.00M
Capital lease obligations 0.00M 0.06M 0.09M 0.13M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -3.56M -6.79M 0.00M -0.00M -
Total cash from financing activities -0.20M 8.51M 1.66M 0.88M 0.73M
Net income -4.65M -1.70M -6.08M -3.40M -5.02M
Change in cash 0.42M -0.50M 0.58M 0.02M 0.05M
Begin period cash flow 0.16M 0.66M 0.08M 0.06M 0.02M
End period cash flow 0.58M 0.16M 0.66M 0.08M 0.06M
Total cash from operating activities -3.84M -2.22M -1.08M -0.86M -0.68M
Issuance of capital stock 0.00M 8.55M 1.43M 0.88M -
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory -0.01M -0.14M -0.01M -0.00M 0.01M
Change to account receivables -0.00M 0.00M -0.01M -0.00M 0.01M
Other cashflows from financing activities -0.20M 8.55M 0.24M 0.08M 0.70M
Capital expenditures 0.11M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.77M -0.63M 0.52M 0.50M 0.29M
Stock based compensation 2.41M 0.27M 4.48M 1.96M 0.56M
Other non cash items -1.09M -0.16M 4.11M 0.01M 3.76M
Free cash flow -3.94M -2.22M -1.08M -0.86M -0.68M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29

Profile*

Nexalin Technology Inc

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

1776 Yorktown, Houston, TX, United States, 77056

832 260 0222

6

Name Title Year Born
Mr. Mark White Pres, CEO & Director 1962
Dr. David Owens M.D. Chief Medical Officer & Director 1962
Mr. John Patrick Claude Co-Founder and Director of Engineering & Devel. NA
Ms. Marilyn Elson Chief Financial Officer 1954
Mr. Joel Bradus Director of Sales & Marketing NA
Ms. Marilyn Elson Controller 1953
Mr. Mark White President, CEO, CFO & Director 1962
Mr. John Patrick Claude Co-Founder and Director of Engineering & Development NA
Dr. David Owens M.D. Chief Medical Officer & Director 1961
Mr. Michael Nketiah Senior Vice-President of Quality, Regulatory & Clinical Affairs 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…